Why Most People Using CBD Are Getting a Fraction of the Dose Ranges Studied in Clinical Research

Most people who have tried CBD and found the results inconsistent were not making a mistake. They were often using a product that delivered a fraction of the dose ranges that clinical researchers have explored.

This is not a marketing claim. It is a documented gap between what retail CBD products deliver and what the clinical literature has examined. Understanding that gap does not tell you whether cannabinoids will work for you. It does explain why the retail experience is structurally different from a clinical one.

Dose is one of the most important variables in how any compound is evaluated clinically. This article explains what the dose gap is, what peer-reviewed research has examined at different dose ranges, why retail products are formulated the way they are, and what a clinical evaluation pathway looks like in relation to dose.

Educational Disclaimer:  This article is for informational purposes only. It is not medical advice. Research citations are provided for educational context only and do not constitute efficacy claims. Not all patients are eligible for clinical evaluation. No guarantee of prescription or outcome. Compounded formulations are not FDA-approved.

Table of Contents

1.  What the dose gap is

2.  What a 2021 survey found about CBD user behavior

3.  What clinical research has examined at higher doses

4.  Why retail products are formulated the way they are

5.  What the dose gap means for patients who tried retail CBD

6.  How dose is handled in a clinical pathway

7.  What the dose gap does not tell us

8.  Frequently asked questions

1. What the Dose Gap Is

The dose gap refers to the documented difference between the amount of cannabidiol found in most retail CBD products and the dose ranges that have been examined in clinical research.

Retail CBD products are typically formulated at serving sizes between 10 and 50 milligrams per dose. Many products fall at the lower end of that range. These serving sizes are set by manufacturers based on regulatory constraints, market pricing, and consumer conventions established in the supplement industry.

Clinical research has explored cannabidiol at substantially higher dose ranges. Studies examining cannabidiol have used doses of several hundred milligrams in many study designs, depending on the research protocol and the population being studied.

The gap between a typical retail serving size of 25 milligrams and a clinical research dose of 300 milligrams is not marginal. It is a substantial difference in scale. A patient who used a 25-milligram retail product and a patient enrolled in a 300-milligram clinical study were not having comparable experiences from a dose perspective.

2. What a 2021 Survey Found About CBD User Behavior

A peer-reviewed cross-sectional study published in the Journal of Cannabis Research in 2021 surveyed 387 CBD users about their use patterns and motivations. The study found that 54 percent of respondents reported taking less than 50 milligrams of CBD daily.

The top reported reasons for using CBD in that study were self-perceived anxiety (42.6 percent), sleep problems (42.5 percent), and stress (37 percent). These are the same concerns that commonly drive patients to seek clinical evaluation.

The study has important limitations. The sample was primarily based in the United Kingdom, with 77.4 percent of respondents located there. The findings may not directly generalize to the US market. The study was a self-report survey, not a clinical trial, and does not establish clinical outcomes at any dose level.

What the study documents is user behavior: the majority of people using CBD products are doing so at dose levels substantially below what clinical research has examined.

3. What Clinical Research Has Examined at Higher Doses

A 2022 systematic review published in Clinical and Translational Science examined published studies using oral CBD doses up to 400 milligrams per day in adult populations. The review evaluated efficacy and safety across multiple conditions.

The review's findings on dose are specific. The authors noted that effects observed in the studies were more frequently reported at dose ranges of 300 milligrams and above. The strongest evidence in the studies reviewed was in the areas of anxiety and substance use disorder. The authors noted that evidence for pain and sleep at these dose ranges was more limited and less consistent.

It is important to be precise about what this research shows and does not show. The review examined published studies that happened to use higher dose ranges. It does not establish that higher doses universally produce better outcomes, that lower doses are ineffective, or that any specific patient will respond at any particular dose. Clinical research in this area is ongoing and significant uncertainties remain.

What the review establishes is that the dose ranges examined in published clinical research differ substantially from the dose ranges found in most retail CBD products. That structural difference is the dose gap.

Arnold et al., Clinical and Translational Science, 2022  |  For educational context only. Not an efficacy claim.

4. Why Retail Products Are Formulated the Way They Are

Retail CBD products are sold as dietary supplements. The supplement industry operates under different regulatory standards than pharmaceutical products. Serving sizes are set by manufacturers, not by clinical guidelines or prescribing clinicians.

Several factors drive the low serving sizes common in retail CBD:

• Cost of goods. Higher CBD concentrations require more raw material and increase production costs.
• Regulatory positioning. Lower doses reduce certain risk considerations for supplement products.
• Consumer pricing expectations. Higher-dose products cost significantly more per unit.
• Market convention. The supplement industry established norms around serving sizes that were not based on clinical research.

None of these factors relate to clinical appropriateness for an individual patient. A manufacturer setting a 25-milligram serving size is making a business and regulatory decision, not a clinical one. There is no clinician reviewing the patient's health history or medications when a retail product is purchased.

This is the structural distinction that the dose gap points to. The retail model was not built around clinical research. It was built around supplement market conventions.

5. What the Dose Gap Means for Patients Who Tried Retail CBD

For patients who used retail CBD products and found the experience underwhelming or inconsistent, the dose gap offers one structural explanation worth considering.

If a patient was using a 25-milligram retail product and the clinical research that has been conducted in areas relevant to their concerns used dose ranges substantially higher, then comparing their retail experience to the clinical literature is not a straightforward comparison. The experiences are structurally different.

This does not mean that higher doses produce better outcomes for every patient. Clinical research does not support that conclusion, and significant individual variability exists. What it means is that the retail experience and the clinical research experience are examining different things, and conclusions drawn from one may not apply to the other.

For patients who are considering whether to explore cannabinoid therapy within a clinical framework, the dose gap is context, not a promise. It explains why the two models are different. It does not predict what will happen for any specific patient in a clinical evaluation.  For many patients, the question is not whether CBD works in general, but whether they have ever used it within a clinically evaluated dose range, with medication review and oversight.

The question for patients:  Not whether cannabinoids work in general. Whether you have ever been evaluated for cannabinoid therapy at a clinically relevant dose range, with medication review, and under clinical supervision.

6. How Dose Is Handled in a Clinical Pathway

In a Prescription Cannabinoid Care model, dose is not set by a manufacturer. It is determined by a licensed clinician based on individual patient evaluation.

The clinical evaluation process reviews the patient's health history, current medications, relevant concerns, and individual clinical context before any dose discussion occurs. Not all evaluations result in a prescription. For those that do, the clinician specifies the dose that is appropriate for that specific patient.

A licensed 503A compounding pharmacy prepares the formulation according to the prescription. This means the formulation is prepared at the specific concentration the clinician has determined appropriate, not at a fixed retail serving size.

Ongoing clinical oversight means that dose can be reassessed over time as the patient's clinical context changes. This is not possible with a retail product that delivers a fixed serving size regardless of individual circumstances.

The clinical pathway does not guarantee any particular dose will be prescribed, or that a prescription will be issued at all. It guarantees that if a prescription is issued, the dose decision was made by a licensed clinician reviewing that specific patient's clinical context.

7. What the Dose Gap Does Not Tell Us

The dose gap is a structural observation. It does not answer several important questions.

It does not tell us that higher doses are better for every patient. Clinical research shows significant variability in individual response, and the appropriate dose for any specific patient depends on factors that a population-level study cannot determine.

It does not tell us that retail CBD users who experienced no benefit would have had a different experience at a higher dose. Individual patient circumstances vary significantly and cannot be extrapolated from group-level research findings.

It does not resolve the broader scientific uncertainties around cannabidiol. Clinical research in this area is ongoing. Cannabidiol is not FDA-approved for the conditions that Cope Now evaluates. Compounded formulations are not FDA-approved. The dose gap exists within a broader landscape of scientific uncertainty that a clinical evaluation cannot resolve, but can help a patient navigate with appropriate oversight.

Understanding the dose gap is the beginning of a clinical conversation, not the end of one.

8. Frequently Asked Questions

Does this mean I should take more retail CBD?

No. This article is not a recommendation to increase retail CBD use. Dose decisions for cannabinoid therapy should be made with a licensed clinician who can review your health history, current medications, and individual clinical context. Self-directed dose escalation without clinical oversight is not what this article is describing.

Why hasn't my doctor told me about the dose gap?

Most clinical training programs did not historically include cannabinoid pharmacology in their curriculum. The endocannabinoid system and CBD pharmacology are relatively recent areas of clinical research. Many clinicians are aware that retail CBD products use low doses but may not have specific knowledge of the clinical research literature on higher dose ranges.

If clinical doses are higher, does that mean they are safer?

Higher dose does not mean safer. The 2022 systematic review found that dose-dependent effects, including adverse effects, also need to be considered. Medication interactions through hepatic enzyme pathways are more clinically relevant at higher doses. This is exactly why clinical evaluation, medication review, and ongoing oversight are part of the Prescription Cannabinoid Care model.

Does the dose gap prove that retail CBD doesn't work?

No. The dose gap is a structural observation about the difference between retail product formulations and clinical research dose ranges. It does not establish that retail CBD products have no effect. Many patients report meaningful experiences with retail CBD products. The dose gap explains one reason why clinical and retail experiences may differ structurally, not that one is ineffective.

What is a clinical evaluation for cannabinoid therapy?

A clinical evaluation is a structured telehealth visit with a licensed clinician who reviews your health history, current medications, and individual concerns to determine whether cannabinoid therapy may be appropriate for your specific situation. Not all evaluations result in a prescription. The evaluation itself has clinical value regardless of the outcome.

How does a compounding pharmacy determine dose?

The compounding pharmacy does not determine dose. The prescribing clinician specifies the dose on the prescription. The pharmacy prepares the formulation at the concentration specified by the clinician. This is how all compounded medications work: the clinician determines what is appropriate; the pharmacy fulfills the prescription.

Are high-dose CBD products available at retail?

Higher-concentration retail CBD products exist but are sold outside a clinical framework. Without clinical evaluation, there is no medication review, no individual dose determination by a clinician, and no ongoing oversight. The dose is one element of a clinical model. The evaluation and oversight are the others.

What conditions does Cope Now evaluate?

Cope Now currently conducts clinician-guided evaluations for patients with concerns related to anxiety, sleep disruption, chronic pain, and recovery. Not all patients who seek evaluation will receive a prescription. The clinician determines what is appropriate based on individual assessment.

This article is for educational purposes only. It is not medical advice. Research citations are provided for educational context only and do not constitute efficacy claims. Cope Now provides access to licensed clinicians for clinical evaluation. Not all patients are eligible. No guarantee of prescription or outcome. Compounded formulations are not FDA-approved. Telehealth services currently available in Colorado only.

Check Your Eligibility

See if a clinical evaluation may be appropriate for you.

References

Moltke J, Hindocha C. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. Journal of Cannabis Research. 2021;3:5. doi:10.1186/s42238-021-00059-7. Note: UK-based sample, n=387. Self-report survey. Does not establish clinical outcomes.

Arnold JC et al. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clinical and Translational Science. 2022;16(1):10-30. doi:10.1111/cts.13425. Note: Systematic review of studies up to 400mg/day. Strongest evidence for anxiety and substance use disorder indications. Evidence for pain and sleep described as more limited and less consistent.